drugset / Trial / NCT07046221
Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery
RandomizedParallel-groupOpen-labelTreatment
Summary
To explore the non-inferiority of the 2y-OS rate of tislelizumab combined with chemotherapy after sequential CRT in the treatment of resectable esophageal squamous cell carcinoma compared with the surgical group
Timeline
- Start
- 2025-08-01
- Primary completion
- 2027-08-01
- Completion
- 2030-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | — |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Subject | Nedaplatin | Small molecule | 80 mg/m2 | — |
| Subject | Nedaplatin | Small molecule | 100 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 125 mg/m2 | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | — |